Month: August 2020

MADISON, Wis., Aug. 11, 2020 (GLOBE NEWSWIRE) — Mediasite today announced its latest learning management system (LMS) integration with e-learning technology Elentra.  Elentra is a platform used by health sciences schools as an LMS, as well as a tool for curriculum management, online exam delivery and more. The new integration lets instructors, staff and authorized students easily record, upload, share and watch Mediasite videos directly in any Elentra course.    “I cannot express how much time is being saved by the integration of Mediasite into Elentra,” said Melissa Tedder, East Carolina University Brody School of Medicine, a Mediasite user. “Thank you for making lecture capture so much more manageable. This is one of my favorite features of Elentra.”  The Elentra-Mediasite integration works similar to other LMSs Mediasite integrates...

TORONTO, Aug. 11, 2020 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has entered into a commercial arrangement with leading Canadian retailer, Fire & Flower Inc. (“Fire & Flower”) (TSX: FAF) (OTCQX: FFLWF). WeedMD will manufacture, package and ship the retailer’s Revity CBD™ product line, expected to be available at Fire & Flower stores in the province of Saskatchewan as of August 14, 2020. Products manufactured through this partnership will be produced at WeedMD’s state-of-the-art extraction hub CX Industries, utilizing the Company’s own input biomass.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d30ebabc-40bd-4c3d-a66a-c55b50dac934“We’re...

EFECTE PLC – STOCK EXCHANGE RELEASE — 11 August 2020 at 13.15Efecte Plc: Change in the publication schedule of the 1-6/2020 half-year report and invitation to a briefingIn deviation from previously published information, Efecte Plc’s half-year report on 1-6/2020 will be published on Tuesday 18 August 2020, approximately at 9.30 Finnish time. The company previously announced that the half-year report will be published on 26 August 2020. The report is published ahead of previously published schedule because the financial results for Q2/2020 are finalized ahead of the previously estimated schedule.An online briefing for analysts, investors and media will be arranged on Tuesday 18 August 2020 at 16.00 Finnish time. All participants can register to the webcast online at investors.efecte.com. The webcast will be held in English and questions...

EFECTE OYJ — PÖRSSITIEDOTE — 11.8.2020 KLO 13.15Efecte Oyj: Muutos puolivuotiskatsauksen 1-6/2020 julkistamisajankohdassa ja kutsu tiedotustilaisuuteenAiemmin ilmoitetusta poiketen Efecte Oyj julkistaa puolivuotiskatsauksen 1-6/2020 tiistaina 18.8.2020 arviolta klo 9.30. Yhtiö on ilmoittanut aiemmin, että puolivuotiskatsaus julkistettaisiin 26.8.2020. Syynä julkistuksen aikaistamiseen on se, että Efecten toisen vuosineljänneksen taloudelliset luvut valmistuvat aikaisemmin arvioitua nopeammin.Analyytikoille, sijoittajille ja medialle järjestetään tiedotustilaisuus verkkoyhteyden välityksellä tiistaina 18.8.2020 klo 16.00. Webcastina järjestettävään tilaisuuteen voivat ilmoittautua kaikki osoitteessa investors.efecte.com.  Webcast järjestetään englanniksi ja kysymyksiä on mahdollista esittää webcast-portaalissa. Tallenne tilaisuudesta...

EFECTE PLC – INSIDE INFORMATION — 11 August 2020 at 13:15Positive profit warning: Efecte Plc updates its guidance for 2020 and announces preliminary information on SaaS net sales growthEfecte expects SaaS net sales to grow 20-25% during 2020, instead of 15-25% as per previous guidance. SaaS demand has remained healthy and the company has through active sales and account management efforts been able to reduce uncertainties related to the pandemic caused by COVID-19.Based on preliminary information, Efecte estimates that the company’s SaaS net sales increased by approximately 22% over the period 1-6/2020. Efecte will publish its half-year report, including more detailed financial information from the period 1-6/2020 on Tuesday 18 August 2020.New guidance for 2020 (from 11 August 2020):In 2020, SaaS net sales is expected to grow between...

EFECTE OYJ — SISÄPIIRITIETO — 11.8.2020 KLO 13.15Positiivinen tulosvaroitus: Efecte Oyj tarkentaa vuoden 2020 ohjeistustaan ja julkaisee ennakkotiedon SaaS-liikevaihdon kasvustaEfecte Oyj odottaa SaaS-liikevaihdon kasvavan 20-25% vuonna 2020, aiemmin ohjeistetun 15-25% sijaan. SaaS-kysyntä on pysynyt hyvänä ja yhtiö on aktiivisen myyntityön ja asiakassuhteiden hoidon kautta onnistunut vähentämään koronaviruspandemiaan liittyviä epävarmuustekijöitä.Alustaviin tietoihin perustuen Efecte arvioi, että jaksolla 1-6/2020 yhtiön SaaS-liikevaihto kasvoi noin 22%. Efecte julkaisee puolivuotiskatsauksensa, mukaan lukien tarkemmat taloudelliset tiedot kaudelta 1-6/2020 tiistaina 18.8.2020.Uusi ohjeistus vuodelle 2020 (11.8.2020 alkaen):Vuonna 2020 SaaS-liikevaihdon odotetaan kasvavan 20-25% ja kannattavuuden parantuvan vertailukaudesta.Aikaisempi...

AMRYT PHARMA PLC(“Amryt” or the “Company”)NOTIFICATION OF CANCELLATION OF ADMISSION TO EURONEXT GROWTHDUBLIN, Ireland, and Boston MA, August 11, 2020, Amryt, (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that it has given Euronext Dublin (“Euronext”) notice of its intention to cancel the admission of the Company’s Ordinary Shares (‘Ordinary Shares”) to trading on the Euronext Growth Market (“Cancellation”). The last day of trading in Ordinary Shares on the Euronext Growth Market will be September 8, 2020 and the Cancellation will take effect at 7.00 a.m. on  September 9, 2020.The Cancellation applies only to the Euronext...

~ No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data ~~ FDA Pre-Approval Inspection has Identified Deficiencies with the Facility of the Drug Product Manufacturer, which Require Resolution Prior to PEDMARK Approval ~~ Company to Host Conference Call and Webcast Today, Tuesday, August 11, 2020, at 8:30 a.m. ET ~RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2020 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on August 10, 2020 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients...

Pivotal Phase 2b/3 trial for BNT162 vaccine program against COVID-19 initiated with first clinical results expected as early as October 2020Initial commercial supply agreements for BNT162 signed with the United States, Japan, Canada and the United Kingdom for more than 250 million doses in 2020 and 2021Published data update for the lead FixVac product candidate BNT111 in Nature and announced a partnership with Regeneron to advance combination therapy with anti-PD-1 into Phase 2 trial in melanomaPresented data for BNT122 Phase 1 trial in multiple solid tumors at AACR Annual Meeting; on track to initiate randomized Phase 2 trials in adjuvant NSCLC and adjuvant CRC by the end of 2020Ended Q2 2020 with cash and cash equivalents of €573 million ($642 million1) and raised an additional €681 million ($762 million1) in gross proceeds from an...

Zulassungsrelevante Phase-2b/3-Studie zu BNT162-Impfstoffprogramm gegen COVID-19 begonnen, erste klinische Ergebnisse werden bereits im Oktober 2020 erwartetErste kommerzielle Lieferabkommen für mehr als 250 Millionen Dosen von BNT162 mit den Vereinigten Staaten, Japan, Kanada und dem Vereinigten Königreich abgeschlossen, die 2020 und 2021 geliefert werdenDaten für den FixVac-Leitkandidaten BNT111 in Nature veröffentlicht sowie Bekanntgabe einer Partnerschaft mit Regeneron zur Weiterentwicklung einer BNT111-Kombinationstherapie mit Anti-PD-1 in Phase-2-Studie in malignem MelanomPräsentation von Daten der BNT122-Phase-1-Studie in verschiedenen soliden Tumorarten auf der Jahrestagung der American Association for Cancer Research (AACR); Start der randomisierten Phase-2-Studien als adjuvante Behandlung im nicht-kleinzelligen Lungenkarzinom...